• The power of local knowledge
    on a global scale.

    No matter where your clinical development takes you, we're already there. Where are you today?

  • We are dedicated to
    the future of clinical development
    and to every life it saves.

    Learn more about why we do what we do, and what we can do for you. Click to read our story.

  • There's just no denying
    good chemistry

    Explore the PRA HEALTH SCIENCES interactive experience to find out what makes us tick.

Social Media

See the latest interactions from our social media


PRA Health Sciences has been involved in the market approval of 12 oncology/hematology drugs. We are...

View Post

Featured News

Read the latest updates from our PR department

PRA Health Sciences Files for Initial Public Offering

08 September 2014, Raleigh, N.C. PRA Health Sciences, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC)...

PRA Health Sciences Expands in Pennsylvania

26 August 2014, Blue Bell, PA – Blue Bell, Pennsylvania will soon be home to PRA Health Sciences’ largest office worldwide. PRA, a leading global Contract Research Organization (CRO), is...

PRA Advances to Become PRA Health Sciences

16 June 2014, RALEIGH, NC – PRA, a leading clinical research organization, today announced that it has changed its name to PRA Health Sciences (PRA). The name change to PRA Health Sciences...

Read More >

Media Resources

Explore the latest resources uploaded to our media library

Sign Up for PRA's Industry Watch

Brought to you by PRA Health Sciences. A Bi-Weekly Industry Watch Newsletter

We Are Dedicated To Minimizing Risk And Protecting Patient Safety
October 1, 2014

Pharmacovigilance solutions for the entire product lifecycle

The Fight Against Alzheimer’s Disease
September 8, 2014

US prevalence of Alzheimer’s Disease is currently at 5 million sufferers and is set to triple by 2050.

Human ADME and Studies with Radiolabeled Compounds: Phase I-IIa
September 1, 2014

Radiolabeled medication is widely used in the assessment of human ADME and also increasingly in assessing absolute bioavailability (BA). Conducting an ADME study early in the clinical development program—generally before or in parallel with Phase IIa—is prudent since the outcome may generate the need for additional toxicology studies.

Strategic Solutions Division: Capabilities & Expertise
September 1, 2014

We deliver clinical development services you need through customized Embedded Solutions™ designed to manage large and mid-size biopharmaceutical companies’ pipeline portfolios more efficiently and with greater flexibility and control.


Find out what's happening next on PRA's event schedule

October 22 - October 23

Evidence USA is the America’s largest and most holistic event on the use of real world outcomes for pharmaceutical products: an exhibition, a series of seminars, and a multi track strategic conference. Speaker: Juliane Mills (Associate Director, Scientific Affairs) Presentation: Optimizing Site Selection and Management for Observational Research

October 27 - October 29

Biosimilars International Conference-2014 provides an in-depth discussion of key industry issues essential to biosimilars including cost effectual development and progression of methods, operation of clinical trials, appraising safety and quality, key strategies for dissolution testing, overcoming regulatory and legal issues and achieving access to emerging markets and commercialising biosimilars. Speaker: Rodeina Challand (Executive Director, Biosimilar […]

October 28 - October 29

The 12th Annual Clinical Trial Supply East Coast 2014 conference is to take place in Princeton on the 28th and 29th October 2014. Building on the growing success of this conference, the 2014 event is set to be the perfect forum for discussion and debate into the biggest challenges currently facing the clinical supply chain. […]

Read More >